Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: A multicenter phase II study

被引：37

作者：

Androulakis, N

Syrigos, K

Polyzos, A

Aravantinos, G

Stathopoulos, GP

Ziras, N

Mallas, K

Vamvakas, L

Georgoulis, V

机构：

[1] Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion 71110, Crete, Greece

[2] Hosp Pulm Dis, Dept Internal Med, Med Oncol Unit 3, Athens, Greece

[3] Laiko Hosp Athens, Med Oncol Unit, Athens, Greece

[4] Agii Anargyri Anticanc Hosp, Dept Med Oncol 3, Athens, Greece

[5] E Dynan Gen Hosp, Med Oncol Unit, Athens, Greece

[6] METAXA Anticanc Hosp, Dept Med Oncol, Athens, Greece

来源：

CANCER INVESTIGATION | 2005年 / 23卷 / 01期

关键词：

oxaliplatin; pancreatic cancer; phase II study;

D O I：

10.1081/CNV-200046502

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A phase II study was designed to evaluate the efficacy and safety of oxaliplatin as second-line treatment in patients with locally advanced or metastatic pancreatic cancer. Eighteen patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy, received oxaliplatin 130 mg/m(2) i.v. every 21 days. Patients were treated until tumor progression or unacceptable toxicity. No objective response was observed among the 18 treated patients. Three (16.7%) patients had stable disease for > 2 months. A clinical benefit response was observed in five (27.7%) patients. Toxicity was mild. Oxaliplatin as second-line treatment for patients with unresectable pancreatic cancer is well tolerated and associated with improvement of tumor-related symptoms despite its failure to induce objective responses. LOHP merits further investigation in combination with other drugs as palliative treatment of pretreated patients with advanced pancreatic cancer.

引用

页码：9 / 12

页数：4

共 25 条

[1] Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study [J].